Viridian Therapeutics won FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease, including both chronic and active phases. The clearance positions Lumvoa as a competitor to Amgen’s Tepezza (teprotumumab-trbw), which previously held the primary approved therapy slot for this indication. The approval is described as including labeling for both disease phases and is tied to a dosing and infusion profile intended to offer a practical alternative. The underlying mechanism is an IGF-1R antagonist, keeping the company in the same targeted class as Tepezza. For biotech buyers and partners, this approval highlights how second-in-class strategies keep opening within established therapeutic areas when regulators accept efficacy and tolerability evidence adequate to support broader labeling. The market impact will depend on adoption against Tepezza’s established use patterns, but the approval extends competitive pressure in a concentrated segment with clear payer relevance.